Navigating Dubai's 2024 Pharmaceutical Conference Circuit


Dubai, recognized as a thriving global center for pharmaceutical and healthcare industries, is gearing up to host a series of impactful conferences in 2024, drawing pharmaceutical professionals and researchers from across the globe. These events are set to unfold in Dubai, offering a platform for experts, professionals, and innovators to converge and exchange cuttingedge insights. Here's an exclusive list of the top 10 pharmaceutical conferences taking place in Dubai in 2024, with DUPHAT securing a spotlight at number 3.


1. Arab Health

Date: January 29  February 1, 2024

Location: Dubai World Trade Centre, UAE

Website: Arab Health


Arab Health stands tall as a premier healthcare exhibition and medical conference in the Middle East. It encompasses diverse topics spanning pharmaceuticals and medical technology, serving as a pivotal gathering for industry professionals.


2. Dubai International Pharmaceuticals and Technologies Conference and Exhibition (DUPHAT)

Date: 9 – 11 January 2024

Location: Dubai International Convention & Exhibition Centre, UAE

Website: DUPHAT


DUPHAT, a celebrated event in the pharmaceutical realm, fosters knowledge exchange among experts, spotlighting the latest strides in pharmaceuticals, technology, and drug manufacturing.


3. Arab International Pharmacy Congress

Date: April 15  April 17, 2024

Website: AIPC 2024


A key congregation for pharmacists and pharmaceutical professionals, this congress delves into the forefront of pharmacy practice, research, and patient care advancements.


4. Middle East Pharmacy and Pharmaceutical Congress

Date: May 5  May 7, 2024

Website: MEPPC 2024


This congress unites pharmaceutical and healthcare sector luminaries to explore emerging trends and present innovative solutions for the industry in the Middle East.


5. Global Pharma Congress

Date: June 10  June 12, 2024

Website: GPC 2024


Focused on the global pharmaceutical market, this conference offers insights into international pharmaceutical regulations, market trends, and best practices.


6. International Conference on Pharmaceutical Research and Drug Development

Date: August 20  August 22, 2024

Website: ICPRDD 2024


Emphasizing the latest research in drug development, clinical trials, and regulatory facets, this conference serves as a prime platform for researchers and scholars.


7. Middle East Pharmaceutical Cold Chain Forum

Date: September 15  September 17, 2024

Website: MEPCCF 2024


Addressing the escalating demand for temperaturesensitive pharmaceuticals, this forum explores logistics and supply chain solutions for product safety and efficacy.


8. Dubai International Conference on Clinical Research

Date: October 5  October 7, 2024

Website: DICCR 2024


Highlighting clinical research significance, this conference underscores ethical, highquality trial conduct in the pharmaceutical and healthcare domains.


9. International Conference on Pharmaceutical and Healthcare Sciences

Date: November 8  November 10, 2024

Website: ICPHS 2024


Encompassing various facets of pharmaceutical and healthcare sciences, this event delves into drug discovery, formulation, and delivery systems.


10. Pharmaceutical Packaging and Drug Delivery Systems Conference

Date: December 12  December 14, 2024

Website: PPDDSC 2024


This conference explores innovations in pharmaceutical packaging and drug delivery systems, focusing on ensuring safe and effective pharmaceutical delivery.


These conferences offer an abundance of insights, networking prospects, and a platform for pharmaceutical and healthcare professionals to stay abreast of industry trends and innovations. Be it researchers, pharmacists, healthcare professionals, or industry experts, these events present a golden opportunity to augment knowledge and contribute to the pharmaceutical field's progress in the Middle East. Join in these monumental gatherings.


Discover Key Insights! Get Up-to-Date with DelevInsight's In-Depth Conference Coverage Today! 

https://www.delveinsight.com/consulting/conference-coverage-services

Comments

Post a Comment

Popular posts from this blog

Japan’s Cancer Drug War: OPDIVO and KEYTRUDA Battle for Dominance

Image
  Analyzing OPDIVO’s Pre-2022 Sales Decline and KEYTRUDA’s Market Ascendancy Before 2022, OPDIVO, developed by Bristol-Myers Squibb (BMS), faced a significant sales decline in Japan’s PD-1 inhibitor market. Despite its initial success, the PD-1 and PD-L1 inhibitors faced challenges from new competitors and evolving market dynamics. One key competitor was Merck's KEYTRUDA, which steadily gained market share due to its broader range of approved indications and successful clinical trial outcomes. KEYTRUDA’s market ascendancy was marked by its approval for various cancers, including melanoma, non-small cell lung cancer, and urothelial carcinoma, among others, making it a versatile choice for oncologists. How OPDIVO Outpaced KEYTRUDA in Japan’s Pharmaceutical Market In 2022, OPDIVO made a remarkable comeback, outpacing KEYTRUDA in Japan’s pharmaceutical market. This resurgence was driven by several strategic moves by BMS. The company expanded OPDIVO’s indications, securing approvals fo
Read more

Unveiling Wainua: A Ray of Hope in the Treatment of HATTR-PN

Image
In the intricate landscape of rare diseases, Transthyretin Amyloidosis (ATTR) stands out as a formidable challenge. Specifically, Hereditary ATTR Amyloidosis with Polyneuropathy (HATTR-PN) presents a complex and often debilitating condition that requires innovative solutions. The quest for effective HATTR-PN treatment has led to the emergence of promising therapies like Wainua, offering a beacon of hope for those grappling with this rare disorder. HATTR-PN , a subtype of ATTR, is characterized by the deposition of misfolded transthyretin proteins, leading to the formation of amyloid plaques in peripheral nerves. This build-up can result in progressive polyneuropathy, impacting the quality of life for those affected. The urgency to address the unmet medical needs of HATTR-PN patients has fueled the development of advanced treatments, with Wainua taking center stage. Wainua represents a breakthrough in ATTR-CM (Cardiomyopathy) treatment , demonstrating potential benefits for HATTR-PN as
Read more